It is evident from Figs. 1 and 2 that there is an upper flat part of the dose response curve for efficacy, starting at sumatriptan 50 mg, and there is no increase in efficacy up to the 300 mg dose.
The long-term efficacy and its stability of its effectiveness of BTX-A in TN was elaborated in two studies [13, 28] which suggested that the effect of a single BTX-A injection could last for 6 mo (24 weeks), whereas other studies showed waning of efficacy started from the 8th week after treatment [28].
Vaccine efficacy starts at the specified efficacy and can evolve over time in either the exponential decay, constant effect for fixed duration, or box-decay patterns.
7. The multidose, double-blinded placebo controlled phase IIb trial designed to assess clinical efficacy started in summer 2012 and was completed 2 years later.
Thus it can be possible to determine loss of efficacy starting from the first RA exacerbation in patients with stable biologic treatment.
The subsequent generations of randomized studies [ 8, 10, 11, 13, 14, 17, 18] showed increased activity and efficacy starting from ORR ≤ 20%, PFS 5 months and OS ≤ 14 months of 5-FU alone.
We limited the analysis to 1 year of treatment with DPP-4 inhibitors for two main reasons: the relation between time and efficacy is linear during the first year 17; and based on long-term RCTs (up to 104 weeks), there seems to be a decline of efficacy starting from the second year of treatment.
"If that happens when Zika vaccine efficacy trials start," he said, "it may take 3 years to show whether it works or not".
Additionally, biomarkers may be used to select patients who have a high likelihood of benefit or they could be used by clinicians to evaluate the potential for efficacy after start of treatment.
A recent meta-analysis evaluated the incremental efficacy of starting nicotine patch treatment prior to cessation, compared with the current regimen of starting patch treatment on the target cessation day.
The efficacy of starting enzyme replacement therapy (ERT) in adults with Muchopolysaccharidosis Type I (MPS-I) is controversial.
